1. Introduction {#sec1}
===============

Obstructive sleep apnea (OSA) is a common and sometimes serious disorder, affecting an estimated 20--30% of men and 10--15% of women [@bib1], [@bib2], [@bib3]. It is characterized by recurrent collapse of the oropharyngeal musculature during sleep, leading to partial or complete obstruction of the upper airway [@bib4]. These changes are most pronounced during rapid eye movement (REM) sleep, when skeletal muscle tone reaches its lowest point, resulting in reduced genioglossus (GG) and intercostal muscle tone and increased susceptibility to upper airway obstruction. Remmers and colleagues provided some of the earliest clinical evidence that GG muscle relaxation is involved in the pathophysiology of obstructive sleep apnea [@bib5]. Several groups have investigated the neuroanatomy and control of GG activity during both sleep and wakefulness, demonstrating that neurons in the hypoglossal motor nucleus (HMN) regulate GG activity [@bib4], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15].

The work of Horner\'s group in Toronto is of particular relevance to the case presented in this paper. He and his colleagues have developed a model of freely-moving, instrumented rodents well-suited for examining the pharmacological manipulation of HMN function. Adding to other work [@bib16], [@bib17], they have recently demonstrated the effects on respiratory muscle activity of stimulation and blockade of HMN α~1~-adrenergic receptors [@bib12]. Microdialysis perfusion with the α~1~-adrenergic agonist phenylephrine increased HMN neuronal and GG activity while perfusion with the α~1~-antagonist terazosin markedly decreased both. These agonistic and antagonistic effects were demonstrated during both wakefulness and sleep.

Alpha~1~-adrenergic antagonists are in common clinical use. Adverse respiratory effects in patients with OSA, including that of reversible airway obstruction, have not been reported to date. In the current case, a patient with stable OSA treated with CPAP received the α~1~-adrenergic antagonist tamsulosin for treatment of benign prostatic hypertrophy (BPH). Tamsulosin dosing was associated with a rapid increase in both the number and severity of symptomatic episodes of airway obstruction. These changes reversed upon discontinuation of the drug.

2. Case {#sec2}
=======

A 67-year old male with a 27-month history of obstructive sleep apnea treated with CPAP presented to the clinic with complaints of fatigue and a marked deterioration of subjective sleep quality, changing as the patient said from "fairly good" to "now very bad". The adverse changes had begun approximately four weeks prior to the clinic visit, with a marked deterioration reported for the most recent seven days. His only other complaint was mild constipation, also beginning during the previous month. The patient had continued his usual professional activities as a physician, although he felt "much less efficient than usual." The patient typically used CPAP between the hours of 11:00 p.m. and 6:00 a.m. He was not a shift worker. He traveled frequently for work, usually involving 3--9 h changes in time zones. He used CPAP during overnight flights. There had, however, been no air travel during the four weeks prior to the clinic visit. He continued to exercise daily. There were no known infectious exposures. He continued to report that he did not smoke, consume alcohol, ingest herbal or natural-product remedies such as yohimbine [@bib18] or use illicit drugs.

Physical examination revealed an alert, mildly fatigued man in no acute distress. Vital signs and the remainder of his examination were normal for his age. In particular, the cardiopulmonary examination was unremarkable. There were no pulmonary or tracheal adventitial breath sounds. The ear/nose/throat examination was also unchanged from his initial presentation (described further below). His weight was 65 kg and BMI 21.8 kg/m^2^. His weight had decreased gradually over 18 months from a peak of 77 kg. Most but not all of the weight loss was described by the patient as voluntary. Epworth Sleepiness Scale (ESS) was 4.

Other medical conditions and medications included:•hypertension for 6 years treated with losartan 100 mg daily•gastroesophageal reflux for 1 year treated with ranitidine 300 mg daily•prostatic hypertrophy for 13 years treated for the most recent nine months with finasteride 5 mg daily to which tamsulosin 0.4 mg daily had been added four weeks before the clinic visit (and which resulted in a 40% increase in peak urinary flow rate after three weeks of dosing)

2.1. Past sleep history {#sec2.1}
-----------------------

The patient originally presented with symptoms of insomnia and severe nocturnal diaphoresis. At initial presentation, the patient\'s physical examination was noteworthy for a slight left inferior nasal septal deviation, a high/narrow hard palate, Mallampati score = 4, class 2 malocclusion with 4 mm overjet, and retrognathia. Diagnostic polysomnography demonstrated an AHI of 21.3, trough oxygen saturation of 84%, oxygen desaturation index of 7.0, and Periodic Limb Movement Index of 45.6. The patient did not report symptoms of restless leg syndrome. There was no other known sleep disorder.

He began empiric CPAP (Resmed^®^ Auto S-9, Rescan™ software Version 5.6.0.9419). The CPAP prescription was then adjusted monthly over the ensuing four months based on detailed outpatient data downloads. The patient reported symptomatic improvement beginning approximately six months after initiation of CPAP. Repeat polysomnography was declined. Minor alterations in CPAP settings were made periodically in an effort to improve patient comfort. Regular follow-up visits demonstrated excellent compliance (98% in year 1 and 97% in year 2 and beyond).

His CPAP prescription on presentation for the current clinic visit had been unchanged for more than six months: auto-PAP 12.6--20 cm H~2~O (1.24--1.96 kPa) with an EPR (expiratory pressure relief) of 1 cm H~2~O (0.098 kPa). There was a 5-min linear pressure ramp to the target minimum from a starting airway pressure of 7 cm H~2~O (0.69 kPa).

2.2. CPAP data {#sec2.2}
--------------

CPAP unit data were available for approximately two years with approximately 85% of nights also having detailed data available. Both detailed and summary data were recorded for all nights during the nine months immediately preceding the clinic visit. During the one-year period preceding the clinic visit (months 16--27 after the formal diagnosis of OSA), AHI averaged 0.8 ± 0.1 (mean ± SD), AI = 0.1, HI = 0.7. The maximal single-night values recorded during this same one-year period were AHI = 2.7, AI = 0.9, and HI = 2.2 (not all occurring on the same night). The patient\'s data for AHI and AI for the three months immediately prior to the tamsulosin dosing period, the period of tamsulosin dosing, and one month after discontinuation appear in [Fig. 1](#fig1){ref-type="fig"}.

On a night-to-night basis, airway obstruction varies in patients with OSA [@bib19]. Although the variability in the current patient\'s data appears to be greater during the on-tamsulosin period, the coefficient of variation is actually similar in both the on- and off-periods (on = 1.6 vs off = 1.3). Notwithstanding this similarity, during the 119 off-tamsulosin days of [Fig. 1](#fig1){ref-type="fig"} AI did not exceed 0.9. Phrased in another way, AI exceeded 0.9 on 0 of 119 days. (A review of historical data showed that AI had not exceeded 0.9 in more than 450 days.) During the on-tamsulosin days in [Fig. 1](#fig1){ref-type="fig"}B, AI exceeded the previous 18 months\' maximum on 9 of 34 days. The probability that this finding regarding days in excess of the prior AI maximum (0 of 119 days vs. 9 of 34 days) is due to chance alone is less than 1 × 10^−8^ (chi-square, Microsoft^**®**^ Excel^**®**^ v14.6.8).

The events during tamsulosin exposure were obstructive rather than central in origin ([Fig. 2](#fig2){ref-type="fig"}).

During the three months preceding initiation of tamsulosin, the patient experienced a total of 93 recorded events (9 obstructive, 84 central). During the approximately one month (34 days) of tamsulosin exposure, the patient experienced 281 events (240 obstructive, 41 central). In the month following discontinuation of tamsulosin there were 62 events recorded (9 obstructive, 53 central). The probability that this increase in both the number and proportion of obstructive events during tamsulosin exposure occurred at random is less than 1 × 10^−10^ (chi-square).

While the absolute values of AHI and AI may appear to be numerically modest, the increased frequency and duration of obstructive events resulted for this patient in both disturbed sleep and compromised cognition. Moreover, the incidence and severity of symptomatic obstruction appeared to be increasing with continued tamsulosin dosing.

More detailed evidence of airway obstruction for the night of the peak AI, and which then resulted in the immediate, next-morning termination of tamsulosin, is shown in [Fig. 3](#fig3){ref-type="fig"}.

Before the initiation of tamsulosin therapy, and from the more than 700 nights of detailed historical CPAP data available for this patient, the combination of persistent high-frequency obstructive events and sustained maximal elevation in airway pressure shown had never been observed.

3. Discussion {#sec3}
=============

The current case report appears to be the first to document a reversible deterioration in the signs and symptoms of OSA following systemic α~1~-adrenergic blockade. The incidence of OSA and its associated morbidity and mortality are significant [@bib1], [@bib2], [@bib3], [@bib20]. An estimated four million men in the United States who have BPH (6% of men over 40) receive one of the α~1~-adrenergic blockers [@bib21], [@bib22]. If these two disorders segregate independently, then there could readily be some 200,000 men in the U.S. with OSA and BPH who are also receiving an α~1~-adrenergic antagonist. Some of these OSA patients will not be treated with CPAP. As a result, the OSA-CPAP/BPH-α~1~-antagonist subset is probably smaller in number and may explain how previous cases - if any - could have been missed. On the other hand, any worsening of sleep quality in patients may not be reported or could be attributed to other more common causes.

From an examination of the current patient\'s data, increased airway obstruction began to appear shortly after tamsulosin dosing was initiated. The half-life of tamsulosin is approximately 15 h [@bib23]. Standard pharmacokinetic-pharmacodynamic modeling [@bib24], [@bib25] would suggest that three or more days of dosing could be required to achieve peak steady-state plasma levels of tamsulosin and a similar period of time to eliminate the drug from circulation. Even if peak levels required several days to establish in the current patient, with continued tamsulosin dosing there was a trend toward progressively higher values in the patient\'s AHI and AI. This suggests the possibility of an increased pharmacodynamic airway response developing over several weeks. The same type of observation -- a progressively greater response to tamsulosin during weeks of exposure -- has been made previously in the population of patients with prostatic hypertrophy [@bib23]. Up to eight weeks of dosing were required to achieve maximal clinical increases in urinary flow rates. Such pharmacodynamic response data also suggest that adverse airway effects could still be observed during the first few days after the final tamsulosin dose, after which -- if tamsulosin were cause of increased airway obstruction - CPAP data would then return to pre-tamsulosin values. This was the pattern observed in the current patient.

There are multiple marketed α~1~-adrenergic antagonists, differing in specificity, receptor affinity and probably in blood-brain-barrier permeability [@bib26]. When adjusted for clinical dose, however, pharmacological effects appear more uniform across the class, at least for indicated uses. Tamsulosin, though, is a drug that partitions into the brain (at least in some species) [@bib27], has high α~1~-receptor specificity and affinity [@bib26], [@bib28], a slow offset from its receptor [@bib29], a prolonged half-life in older patients [@bib23], and reduced clearance in some patients who concomitantly receive, as the current patient did, an H~2~-antagonist like ranitidine [@bib23]. These pharmacological characteristics of tamsulosin, and perhaps the concomitant use of ranitidine, may substantially account for the observations in the current case.

While the preceding drug-specific considerations support a role for tamsulosin in precipitating the respiratory compromise observed in this patient, it is appropriate to ask if there were also patient-specific contributory factors. There is adrenergic genetic variation of relevance to OSA. However, it is a polymorphism in the β~1~-, and not the α~1~-, adrenergic receptor that has been identified as important, at least in those patients who also have - like the patient of this report - hypertension [@bib30]. In addition, the current patient\'s BMI had decreased meaningfully from approximately 25 to 21 while on CPAP during the 18 months preceding the initiation of tamsulosin therapy. A significant weight loss in an OSA patient beginning with a normal-range BMI could perhaps unfavorably alter genioglossus mass or strength [@bib31], [@bib32]. If so, then in this patient any sensitivity to adverse muscular effects from α~1~-adrenergic blockade may have been increased.

The strengths of this report include the availability of extensive and detailed data: longitudinal clinical recordings of airway pressures, flows, and obstructive events from hundreds of nights preceding initiation of α~1~-adrenergic blockade with tamsulosin and similarly detailed data during and after tamsulosin exposure. The observed pattern of airway obstruction in this patient (onset, worsening, and offset) fit well with known tamsulosin pharmacokinetics. Finally, preclinical data from multiple laboratories have identified α~1~-adrenergic blockade as a plausible mechanism for interference with genioglossus activity and consequential airway obstruction.

Potential weaknesses of the report include the absence of clinical reports for other drugs in the same class and the unavoidable fact that data from laboratory models cannot substitute for their clinical counterparts. Whether a second polysomnography could have yielded probative data for this patient that would have altered the apparent response to tamsulosin is, of course, unknown.

It is very unlikely that the reversible obstruction observed in this patient occurred at random. The only known pharmacological changes were tamsulosin administration and withdrawal. The clinical changes were consistent with preclinical observations. The onset and offset of adverse respiratory effects were compatibly timed with tamsulosin exposure. The statistics are familiar, simple, and robust. In brief, one month\'s exposure to the α~1~-adrenergic antagonist tamsulosin was associated with a reversible deterioration in the signs and symptoms of obstructive sleep apnea.

The author thanks Mitchell Miglis, M.D., Stanford University School of Medicine, for his comments.

![Values for AHI (panel A) and AI (panel B) are shown by night in monthly intervals before and after tamsulosin exposure ("off tamsulosin", blue dashes) and during tamsulosin exposure ("on tamsulosin", AHI solid red diamonds, AI solid red circles). The on-tamsulosin data points begin with the first dose of tamsulosin and, to accommodate the time needed to clear tamsulosin from the body, continue until four days after the final tamsulosin dose. As shown, both AHI and AI had been low and stable for months prior to the initiation of dosing with tamsulosin. Within two days after the first dose of tamsulosin, both AHI and AI exceeded values that had not been exceeded for months. Both AHI and AI reached apex values just before tamsulosin dosing was terminated specifically because of these changes and attendant symptoms. After termination of tamsulosin, AHI and AI declined over several days, returning to and then remaining at pre-tamsulosin levels (During the five calendar months shown in [Fig. 1](#fig1){ref-type="fig"}, the patient used CPAP for a total of 1064:06 h:min, for an average of 6 h 57 min per night, \>4 h per night on 153 nights, \<4 h per night on 0 nights.). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr1){#fig1}

![The number of central events (panel A) and obstructive events (panel B) by night in monthly intervals before and after tamsulosin exposure ("off tamsulosin", blue dashes) and during tamsulosin exposure ("on tamsulosin", solid red diamonds \[central events\] or solid red circles \[obstructive events\]). The on-tamsulosin data points begin with the first dose of tamsulosin and, to accommodate the time needed to clear tamsulosin from the body, continue until four days after the final tamsulosin dose. The incidence of central events did not change with α~1~-adrenergic blockade while both the incidence and duration (not shown) of obstructive events increased markedly during tamsulosin exposure. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr2){#fig2}

![Detailed CPAP device data output (ResScan™) from 25 November 2015 after what proved to be the final dose of tamsulosin on the evening of 24 November 2015. Data collection began at 00:15 a.m. and ended at 06:39 a.m., a total of 6 h 24 min. Airway pressure was maintained at the machine maximum of 20 cm H~2~O (1.96 kPa\*) for approximately 3h 20 min (52% of the total data collection time). Median leak rate for the night was 9.6 L/min. Leak exceeded 24 L/min for fewer than 20 min. AHI peaked at 23 events/h, almost entirely due to episodes of obstruction (red arrows), each obstructive event lasting 10--46 s, with the majority lasting 25 s or longer. Note that when the obstructive event rate was at its highest, between 04:15 and 06:39 a.m., the leak rate was near its lowest for the night. \[\*Multiply cm H~2~O by 0.098 to convert to kPa.\].](gr3){#fig3}
